Lazard Asset Management LLC Macrogenics Inc Transaction History

Lazard Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $46,879 - $76,508	-10,147 Reduced 75.38%	3,315 $17,000
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $6,694 - $10,056	1,389 Added 11.51%	13,462 $96,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $40,323 - $84,269	12,073 New	12,073 $81,000
Q4 2021 Feb 09, 2022	SELL	$15.91 - $21.88 $33,379 - $45,904	-2,098 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $41,414 - $60,212	2,098 New	2,098 $43,000
Q2 2021 Aug 12, 2021	SELL	$20.49 - $35.63 $49,032 - $85,262	-2,393 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$18.99 - $33.2 $45,443 - $79,447	2,393 New	2,393 $76,000

133

55.5M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $175M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.